US20240173360
2024-05-30
Human necessities
A61K35/741
Pharmaceutical compositions have been developed to treat epilepsy and related disorders in mammals. These compositions utilize non-pathogenic fecal microbes, which are believed to play a crucial role in restoring balance to the gut microbiota. The methods aim to provide effective treatment for individuals suffering from epilepsy and epileptic seizures.
The gastrointestinal tract hosts a diverse range of microbial species that interact with the host's immune system. A healthy microbiota supports various bodily functions, including pathogen resistance and nutrient absorption. Dysbiosis, or an unbalanced microbiota, can lead to increased susceptibility to infections and other health issues, highlighting the significance of maintaining a healthy gut environment.
FMT is a therapeutic approach that involves transferring human colonic microbiota into patients to restore a healthy microbial community in the gut. This method has shown effectiveness in treating infections like Clostridium difficile and is being explored for its potential benefits in managing other conditions, including epilepsy.
Various methods have been proposed for administering therapeutic compositions derived from fecal bacteria. These include oral capsules containing live non-pathogenic bacteria or sterile fecal filtrates. Dosing schedules may vary, with recommendations for administration at least once or twice daily over several weeks to achieve optimal therapeutic effects.
The treatment methods also involve assessing the abundance of specific gut microbial species, such as Akkermansia or Parabacteroides. If their levels fall below a certain threshold, oral administration of the therapeutic compositions may be indicated. This targeted approach aims to enhance the effectiveness of treatments for epilepsy and seizures by focusing on restoring key microbial populations in the gut.